About this trial
Lichen Sclerosus (LS) is a common genital skin condition that severely impacts on daily living. LS occurs worldwide but may be more common in the white population. The extragenital skin is involved in about 10% of reported patients, exact numbers are not known. LS is estimated to affect 0.1-0.3% of new patients in a general hospital patient population and 1.7% of patients referred to general gynaecological practice, however, the exact prevalence and incidence is not known. LS has a major impact on the quality of life, as symptoms of itching, pain and discomfort can make it difficult to sit, walk and go to the toilet. Having sex becomes painful because of erosions and fissures (break down of the skin), sometimes impossible because of irreversible fusion (sticking together) and sclerosis (hardening) of the genital skin. There is an increased risk of genital cancer in individuals with LS, this seems higher in familial cases. Next to a genetic background leading to a dysregulation of the immune system, certain external trigger mechanisms seem to play an important role in the development of LS.
In this project the investigators propose to identify pathogenic variants in novel protein-coding genes that may be involved in Lichen sclerosus using samples from families with members manifesting LS. Through elucidating underlying pathomechanims which have not yet been fully explored the development of novel treatments may be possible.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individual with clinical or /and histological Lichen sclerosus
Family member of an individual with lichen sclerosus
Disqualifiers
No Family member with lichen sclerosus
Trial population
Cohort of families with lichen sclerosus
Trial design
Cohort
Prospective
Treatments tested in this trial
No Interventions
Other interventionthis is no interventional study
Treatment groups
Trial outcomes
Primary outcomes
Identification of novel Lichen sclerosus genes
Our project does not have classical primary and secondary endpoints as we are not following one or multiple parameters and because we are not within a clinical trial frame. Our primary endpoint will be having sequenced the exome/genome of families with LS and solved the segregation of variants of interest in the rest of the pedigree "Number of Participants with potential LS genes". The secondary endpoint will be the identification of novel LS genes "Number of genes associated with LS identified".
Secondary outcomes
Novel Lichen sclerosus genes
The secondary endpoint will be the identification of novel LS genes "Number of genes associated with LS identified".
Other outcomes
Novel LS genes
Our project does not have classical primary and secondary endpoints as we are not following one or multiple parameters and because we are not within a clinical trial frame. Our primary endpoint will be having sequenced the exome/genome of families with LS and solved the segregation of variants of interest in the rest of the pedigree. The secondary endpoint will be the identification of novel LS genes.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Gudula Kirtschig
Lead sponsor
Medbase
Sponsor institution
Medbase
Collaborator
CECAD Research Center
Collaborator
Gyn-Zentren, Luzern und Cham
Collaborator
Klinik für Kinderurologie in Kooperation mit der Universität Regensburg Krankenhaus Barmherzige Brüder Regensburg - Klinik St. Hedwig
Collaborator